Issues in the design and implementation of vaccine trials in less developed countries

被引:12
作者
Deen, Jacqueline L. [1 ]
Clemens, John D. [1 ]
机构
[1] Int Vaccine Inst, Seoul, South Korea
关键词
D O I
10.1038/nrd2159
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
There is a growing need for vaccine trials in developing countries. This need arises from the fact that some vaccines do not perform as well in developing as in industrialized country populations and because some newly developed candidates target diseases found only in less-developed countries. Here we discuss several key issues in the design and implementation of vaccine trials in less-developed countries. These include the phasing of vaccine trials on safety, immunogenicity and efficacy to achieve licensure; the recent use of trials to obtain other information crucial to the ultimate deployment of vaccines ( such as immunological correlates of protection, indirect vaccine effects, and practical information on the feasibility, costs and acceptability of vaccine introduction); and several ethical issues that have arisen in connection with trials done in developing countries.
引用
收藏
页码:932 / 940
页数:9
相关论文
共 63 条
[1]   Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine:: a prospective study [J].
Adegbola, RA ;
Secka, O ;
Lahai, G ;
Lloyd-Evans, N ;
Njie, A ;
Usen, S ;
Oluwalana, C ;
Obaro, S ;
Weber, M ;
Corrah, T ;
Mulholland, K ;
McAdam, K ;
Greenwood, B ;
Milligan, PJM .
LANCET, 2005, 366 (9480) :144-150
[2]   Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis [J].
Ali, M ;
Emch, M ;
von Seidlein, L ;
Yunus, M ;
Sack, DA ;
Rao, M ;
Holmgren, J ;
Clemens, JD .
LANCET, 2005, 366 (9479) :44-49
[3]   Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children:: randomised controlled trial [J].
Alonso, PL ;
Sacarlal, J ;
Aponte, JJ ;
Leach, A ;
Macete, E ;
Milman, J ;
Mandomando, I ;
Spiessens, B ;
Guinovart, C ;
Espasa, M ;
Bassat, Q ;
Aide, P ;
Ofori-Anyinam, O ;
Navia, MM ;
Corachan, S ;
Ceuppens, M ;
Dubois, MC ;
Demoitié, MA ;
Dubovsky, F ;
Menéndez, C ;
Tornieporth, N ;
Ballou, WR ;
Thompson, R ;
Cohen, J .
LANCET, 2004, 364 (9443) :1411-1420
[4]  
Anderson R.M., 1995, INFECT DIS HUMANS DY
[5]  
[Anonymous], 2005, MMWR Morb Mortal Wkly Rep
[6]  
[Anonymous], ETH POL ISS INT RES
[7]  
[Anonymous], 1996, ICH HARM TRIP GUID G
[8]  
AQABY P, 1988, LANCET, V2, P809
[9]   Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule [J].
Avdicová, M ;
Prikazsky, V ;
Hudecková, H ;
Schuerman, L ;
Willems, P .
EUROPEAN JOURNAL OF PEDIATRICS, 2002, 161 (11) :581-587
[10]   Sustainable introduction of affordable new vaccines: the targeting strategy [J].
Batson, A .
VACCINE, 1998, 16 :S93-S98